Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
MAGE-A1 Double Nickase Plasmid (h): sc-401056-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- MAGE-A1 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- MAGE-A1 Double Nickase Plasmid (h) and MAGE-A1 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting MAGEA1. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: MAGE-A1 Antibody (MA454): sc-20033
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MAGE-A1 Double Nickase Plasmid (h) | sc-401056-NIC | 20 µg | $410.00 | |||
MAGE-A1 Double Nickase Plasmid (h2) | sc-401056-NIC-2 | 20 µg | $410.00 |
MAGEA1 encodes MAGE-A1, a cancer-testis antigen normally restricted to immune-privileged germline tissues but aberrantly expressed in multiple tumor types, making it a widely used marker for tumor-associated transcriptional programs. MAGE-A1 can engage with E3 ubiquitin ligases and related protein quality-control machinery, linking it to regulation of protein stability, stress responses, and context-dependent control of cell signaling. Its expression is influenced by epigenetic mechanisms such as DNA methylation and chromatin remodeling, connecting MAGEA1 to pathways governing transcriptional repression and derepression. In research settings, MAGEA1 is studied for roles in antigen presentation and immune recognition, tumor cell plasticity, and how epigenetic dysregulation enables lineage-inappropriate gene expression.
MAGE-A1 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the MAGEA1 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within MAGEA1. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt MAGEA1 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of MAGEA1-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.